{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:35:55Z","timestamp":1780583755802,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":78,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.100905","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T03:04:57Z","timestamp":1742699097000},"page":"100905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-1947","authenticated-orcid":false,"given":"Antonio","family":"Calles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirian","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Mart\u00edn-Martorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Mart\u00ednez-Aguillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Estival","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Mosquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natividad","family":"Mart\u00ednez-Banaclocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Majem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eider","family":"Azkona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Laura","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Aguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Cucurull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Isla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Sais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Juan-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MPilar","family":"Diz-Ta\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Taus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bayona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Amenedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xabier","family":"Mielgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Arriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Baena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctarc.2025.100905_bib0001","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","article-title":"ALK-positive lung cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat. Cancer"},{"issue":"11","key":"10.1016\/j.ctarc.2025.100905_bib0002","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jtho.2017.08.002","article-title":"Recent Advances in Targeting ROS1 in Lung Cancer","volume":"12","author":"Lin","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100905_bib0003","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2025.100905_bib0004","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/curroncol29020057","article-title":"ROS-1 Fusions in Non-Small-Cell Lung Cancer: evidence to Date","volume":"29","author":"Gendarme","year":"2022","journal-title":"Curr. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2025.100905_bib0005","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.20.03025","article-title":"Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer","volume":"39","author":"Dziadziuszko","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2025.100905_bib0006","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann. Oncol."},{"issue":"21","key":"10.1016\/j.ctarc.2025.100905_bib0007","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100905_bib0008","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40265-018-1041-0","article-title":"Lorlatinib: first Global Approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ctarc.2025.100905_bib0009","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2025.100905_bib0010","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100905_bib0011","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, <em>ALK<\/em>-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"The Lancet Respiratory Medicine (Baltimore)"},{"issue":"21","key":"10.1016\/j.ctarc.2025.100905_bib0012","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ctarc.2025.100905_bib0013","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2025.100905_bib0014","unstructured":"Network NCC. Non-Small Cell Lung Cancer (Version 3.2025) [Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"issue":"8","key":"10.1016\/j.ctarc.2025.100905_bib0015","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1007\/s12325-024-02899-6","article-title":"Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC","volume":"41","author":"Arnaoutakis","year":"2024","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.ctarc.2025.100905_bib0016","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study","volume":"29","author":"Novello","year":"2018","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2025.100905_bib0017","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.annonc.2021.02.012","article-title":"Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs","volume":"32","author":"Felip","year":"2021","journal-title":"Ann. Oncol."},{"issue":"32","key":"10.1016\/j.ctarc.2025.100905_bib0018","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.20.01255","article-title":"Survival in Patients With Brain Metastases: summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient","volume":"38","author":"Sperduto","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2025.100905_bib0019","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.jtho.2020.04.019","article-title":"An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC","volume":"15","author":"Zhu","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100905_bib0020","article-title":"LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC","volume":"4","author":"Alexander","year":"2023","journal-title":"JTo Clin. Res. Rep."},{"key":"10.1016\/j.ctarc.2025.100905_bib0021","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejca.2022.01.018","article-title":"Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: results of the IFCT-1803 LORLATU cohort","volume":"166","author":"Baldacci","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2025.100905_bib0022","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fonc.2020.01299","article-title":"Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients","volume":"10","author":"Britschgi","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2025.100905_bib0023","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920980558","article-title":"Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program","volume":"13","author":"Frost","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ctarc.2025.100905_bib0024","doi-asserted-by":"crossref","DOI":"10.1111\/cas.15777","article-title":"Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer","author":"Goto","year":"2023","journal-title":"Cancer Sci."},{"issue":"11","key":"10.1016\/j.ctarc.2025.100905_bib0025","article-title":"Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: a Retrospective","volume":"13","author":"Hochmair","year":"2020","journal-title":"Multicenter Analysis. Pharmaceuticals (Basel)."},{"key":"10.1016\/j.ctarc.2025.100905_bib0026","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2020.07.022","article-title":"GLASS: global Lorlatinib for ALK (+) and ROS1 (+) retrospective Study: real world data of 123 NSCLC patients","volume":"148","author":"Peled","year":"2020","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.ctarc.2025.100905_bib0027","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1158\/2159-8290.CD-24-0231","article-title":"NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations","volume":"14","author":"Lin","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ctarc.2025.100905_bib0028","doi-asserted-by":"crossref","first-page":"S802","DOI":"10.1016\/j.annonc.2024.08.1310","article-title":"1253O Phase I\/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours","volume":"35","author":"Drilon","year":"2024","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1016\/j.ctarc.2025.100905_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100418","article-title":"Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study","volume":"7","author":"Girard","year":"2022","journal-title":"ESMo Open."},{"issue":"6","key":"10.1016\/j.ctarc.2025.100905_bib0030","article-title":"Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTo Clin. Res. Rep."},{"issue":"10","key":"10.1016\/j.ctarc.2025.100905_bib0031","article-title":"Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC","volume":"3","author":"Wu","year":"2022","journal-title":"JTo Clin. Res. Rep."},{"issue":"2","key":"10.1016\/j.ctarc.2025.100905_bib0032","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.100905_bib0033","doi-asserted-by":"crossref","first-page":"S821","DOI":"10.1016\/j.annonc.2024.08.1346","article-title":"1289P Pooled efficacy and safety from 2 pivotal phase II trials of taletrectinib in patients (Pts) with advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC)","volume":"35","author":"P\u00e9rol","year":"2024","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ctarc.2025.100905_bib0034","doi-asserted-by":"crossref","first-page":"S804","DOI":"10.1016\/j.annonc.2024.08.1313","article-title":"1256MO Phase I\/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours","volume":"35","author":"Besse","year":"2024","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1016\/j.ctarc.2025.100905_bib0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","article-title":"ROS1-dependent cancers - biology, diagnostics and therapeutics","volume":"18","author":"Drilon","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2025.100905_bib0036","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jtho.2018.05.026","article-title":"Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice","volume":"13","author":"Park","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2025.100905_bib0037","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtho.2018.07.001","article-title":"The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib","volume":"13","author":"Patil","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2025.100905_bib0038","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.lungcan.2020.02.011","article-title":"Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer","volume":"144","author":"Peters","year":"2020","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.ctarc.2025.100905_bib0039","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40261-024-01379-7","article-title":"Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer","volume":"44","author":"Arriola","year":"2024","journal-title":"Clin. Drug Investig."},{"issue":"7","key":"10.1016\/j.ctarc.2025.100905_bib0040","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.3390\/curroncol30070481","article-title":"Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience","volume":"30","author":"Rupp","year":"2023","journal-title":"Curr. Oncol."},{"issue":"16","key":"10.1016\/j.ctarc.2025.100905_bib0041","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2025.100905_bib0042","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-21-0032","article-title":"Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer","volume":"27","author":"Lin","year":"2021","journal-title":"Clin. Cancer Res."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T18:57:55Z","timestamp":1762628275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225000425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":42,"alternative-id":["S2468294225000425"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100905","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100905"}}